Syntekabio Inc. An NGS and AI Drug Discovery and Development Company Syntekabio, headquartered in Daejon, South Korea, is an AI (Artificial Intelligence) and NGS (Next Generation Sequencing) based drug discovery and development company, utilizing a genomic database and AI technology with wholly-owned supercomputing system to predict and identify new molecular entities to be a relevant new drug product. Syntekabio is deeply dedicated to delivering innovative therapies that significantly extend and improve lives and collaborating with various academic institutions, industrial companies, and government research labs worldwide. Syntekabio USA represents Syntekabio and is located at Manhattan, New York, NY, USA. - DeepMatcher™ "Syntekabio pursues innovation in various areas of independent AI drug discovery and development." DeepMatcher™(DMC), AI drug discovery cloud platform, derives active substances through search for available hundreds of millions of manufacturable compound libraries. DMC enables accurate and efficient discovery of new drug candidates as a platform from hit-discovery to lead-optimization, secondary target and off-target analysis, and development of drug resistance biomarkers. - NEO-ARS™ NEO-ARS is an automatic reporting system to predict neoantigens with high accuracy from tumor and blood genome data of cancer patients using an AI-based data algorithm. Unlike existing algorithms that predict neoantigens based on 2D amino acid sequence information, NEO-ARS improves accuracy by predicting immunogenicity on 3D protein structures through supercomputing system. Neoantigen-based immunotherapy can be developed in the form of an anticancer vaccine that directly administers the new antigen or a cell therapy that administers the immune cells of a patient activated outside the body with the neoantigen. It is expected to greatly improve the response rate.